×
Cytek Biosciences SG&A Expenses 2021-2025 | CTKB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cytek Biosciences sg&a expenses from 2021 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Cytek Biosciences SG&A Expenses 2021-2025 | CTKB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cytek Biosciences sg&a expenses from 2021 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$220.6B
Amgen (AMGN)
$158.8B
Gilead Sciences (GILD)
$136.4B
Vertex Pharmaceuticals (VRTX)
$120.4B
Bristol Myers Squibb (BMY)
$95.4B
GSK (GSK)
$78.4B
CSL (CSLLY)
$76.6B
Regeneron Pharmaceuticals (REGN)
$61.3B
Alnylam Pharmaceuticals (ALNY)
$41.1B
Argenex SE (ARGX)
$34.2B
BioNTech SE (BNTX)
$27.1B
Royalty Pharma (RPRX)
$20.2B
Biogen (BIIB)
$19.7B
Insmed (INSM)
$18.6B
Illumina (ILMN)
$15.7B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.7B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$13B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Roivant Sciences (ROIV)
$7.7B
Repligen (RGEN)
$7.3B